Tonix Pharmaceuticals sets price for $20 million direct offering

Tonix Pharmaceuticals Holding Corp., a company specializing in biotechnology, recently announced a significant development in its financial dealings. This involves a securities purchase agreement with Point72 for the sale and purchase of a substantial number of shares. Specifically, the agreement covers 615,025 shares of common stock at a unit price of $16.26 per share. In addition to the share purchase, there is an arrangement for pre-funded warrants that allow the acquisition of up to 615,025 shares of common stock. The individual price for each pre-funded warrant is $16.259. The offering is expected to close around December 30, 2025, contingent on various standard closing conditions. The gross proceeds from this agreement are anticipated to be approximately $20.0 million. After accounting for placement agent fees and other associated expenses, the net proceeds will be directed towards various company initiatives, including supporting the commercialization of existing products, advancing product pipeline projects, and sustaining corporate operations.

The primary intent behind this offering is to bolster Tonix Pharmaceuticals’ financial resources. By securing this additional funding, the company is better equipped to streamline its operations and sustain its growth trajectory. The involvement of Point72 as a partner in this financial transaction signifies a crucial milestone in Tonix’s strategic financial planning. The confidence shown by Point72 in investing in Tonix reflects positively on the company’s standing within the biotechnology sector.

TD Cowen serves as the exclusive placement agent for this offering, ensuring that the transaction adheres to established regulatory frameworks and industry guidelines. With A.G.P./Alliance Global Partners on board as financial advisors, Tonix is well-positioned to navigate the intricacies of this financial agreement. The involvement of these key partners underscores the meticulous planning and due diligence that underpin Tonix’s financial decisions.

This offering is facilitated through an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Compliance with regulatory requirements and adherence to stipulated guidelines are essential components of this transaction. The prospectus supplement detailing the specifics of this offering will be available on the SEC’s official website for access by relevant stakeholders. It is imperative to note that this press release does not equate to a solicitation of purchase and does not imply an offer to sell securities. Any sale of securities is contingent on fulfilling registration or qualification requirements as mandated by relevant regulatory authorities.

Tonix Pharmaceuticals stands out as a fully integrated biotechnology entity, boasting a diverse portfolio of marketed products and development candidates. Central to its product offerings is TONMYA™, an FDA-approved medication designed to alleviate fibromyalgia symptoms. The significance of TONMYA™ lies in being the first prescription medicine approved for fibromyalgia within the last 15 years. Reaffirming the company’s commitment to innovation, Tonix also markets treatments for acute migraine in adults. The development pipeline includes promising ventures focused on addressing central nervous system (CNS) disorders, immunology, immuno-oncology, rare diseases, and infectious diseases.

Tonix’s dedication to pioneering medical solutions is underscored by its ongoing initiatives across various therapeutic areas. For instance, TNX-102 SL is being explored for its potential in treating acute stress reaction and major depressive disorder. In the realm of immunology, Tonix is spearheading projects aimed at combating organ transplant rejection, autoimmunity, and cancer. The company’s rare disease portfolio features TNX-2900, presently under evaluation for Prader-Willi syndrome. Additionally, a robust infectious disease portfolio includes TNX-801 and TNX-4800, both targeting severe medical conditions with the intent to enhance military readiness in biological threat environments. This distinguished lineup of products underscores Tonix Pharmaceuticals’ commitment to advancing healthcare solutions across a spectrum of challenging medical conditions.

In closing, the recent financial offering by Tonix Pharmaceuticals signals a pivotal moment in the company’s growth trajectory. As it forges ahead with strategic financial partnerships and sharpens its focus on product development and commercialization, Tonix is poised to make enduring strides in the competitive landscape of biotechnology. This development underscores Tonix’s unwavering commitment to excellence and innovation within the biopharmaceutical industry.